Mikhail Blagosklonny: различия между версиями

(не показаны 2 промежуточные версии этого же участника)

Строка 15:

== Editorial activities==

Blagosklonny is editor-in-chief of Aging, Cell Cycle, and Oncotarget. In addition, he is associate editor of Cancer Biology & Therapy~~[9]~~ and a member of the editorial board of Cell Death & Differentiation.

Blagosklonny is editor-in-chief of Aging, Cell Cycle, and Oncotarget. In addition, he is associate editor of Cancer Biology & Therapy and a member of the editorial board of Cell Death & Differentiation.

The peer review process employed by Oncotarget has been criticized by Jeffrey Beall,a university librarian and expert on predatory open access publishing, who also included Oncotarget and Aging on his list of "potential, possible, or probable predatory scholarly open-access journals" in July 2015. Further reports on Beall's blog suggest that the substandard peer review processes for these journals are used by their respective editors-in-chief to entice prospective authors to include references to Blagosklonny's own publications in their articles (following the peer review), thereby raising his personal citation impact.

Строка 21:

==Health==

Blagosklonny announced that in January 2023 he was diagnosed with numerous metastases of lung cancer in his brain.~~<ref>{{cite web |url=https://www.mikhailblagosklonny.com/blog/my-battle-with-cancer/|title = My battle with cancer|date = 26 October 2023}}</ref>~~ He died in October 2024 at the age of 63.~~<ref>{{cite web|url=https://www.rapamycin.news/t/passing-of-dr-misha-blagoskonny/16658|title=Passing of Dr. Misha Blagoskonny|work=Rapamycin News|access-date=2024-10-09}}</ref>~~

Blagosklonny announced that in January 2023 he was diagnosed with numerous metastases of lung cancer in his brain. He died in October 2024 at the age of 63.

~~==References==~~

~~{{reflist|30em}}~~

* {{Wikipedia|Mikhail Blagosklonny}}

@@ Строка 15: / Строка 15: @@
 == Editorial activities==
-Blagosklonny is editor-in-chief of Aging, Cell Cycle, and Oncotarget. In addition, he is associate editor of Cancer Biology & Therapy[9] and a member of the editorial board of Cell Death & Differentiation.
+Blagosklonny is editor-in-chief of Aging, Cell Cycle, and Oncotarget. In addition, he is associate editor of Cancer Biology & Therapy and a member of the editorial board of Cell Death & Differentiation.
 The peer review process employed by Oncotarget has been criticized by Jeffrey Beall,a university librarian and expert on predatory open access publishing, who also included Oncotarget and Aging on his list of "potential, possible, or probable predatory scholarly open-access journals" in July 2015. Further reports on Beall's blog suggest that the substandard peer review processes for these journals are used by their respective editors-in-chief to entice prospective authors to include references to Blagosklonny's own publications in their articles (following the peer review), thereby raising his personal citation impact.
@@ Строка 21: / Строка 21: @@
 ==Health==
-Blagosklonny announced that in January 2023 he was diagnosed with numerous metastases of lung cancer in his brain.<ref>{{cite web |url=https://www.mikhailblagosklonny.com/blog/my-battle-with-cancer/|title = My battle with cancer|date = 26 October 2023}}</ref> He died in October 2024 at the age of 63.<ref>{{cite web|url=https://www.rapamycin.news/t/passing-of-dr-misha-blagoskonny/16658|title=Passing of Dr. Misha Blagoskonny|work=Rapamycin News|access-date=2024-10-09}}</ref>
+Blagosklonny announced that in January 2023 he was diagnosed with numerous metastases of lung cancer in his brain. He died in October 2024 at the age of 63.
-==References==
-{{reflist|30em}}
 * {{Wikipedia|Mikhail Blagosklonny}}